News Release

News Release

• September 16, 2026

  ANTINEOPLASTIC AGENT MODEYSO® Capsules 125 mg Marketing Approval in Japan for the Treatment of Diffuse Midline Glioma
• February 16, 2026

  MHLW Grants Orphan Drug Designation and Priority Review for Dordaviprone Hydrochloride (Domestic Development Code: OP-10) in Japan
• January 30, 2026

  Notice of Filing for Manufacturing and Marketing Authorization Dordaviprone Hydrochloride (Domestic Development Code: OP-10)
• June 30, 2025

  Capital Increase by JIC Venture Growth Fund 2
• June 20, 2024

  Additional Investment in Revital Healthcare (EPZ) Limited
• December 19, 2023

  Announcement of Recapitalization of Africa Healthcare Network (AHN)-Expansion of healthcare infrastructure through the development of dialysis services in sub-Saharan countries
• September 27, 2021

  Glucarpidase (Genetical Recombination) “Megludase® ”Marketing Authorization Approval
• June 23, 2021

  Recombinant Chimeric Monoclonal Antibody "Unituxin®" Marketing Authorization Approval
• March 29, 2021

  Glucarpidase (Genetical Recombination)"OP-07" Application Filed for Marketing Authorization for Methotrexate Intoxication
• February 25, 2021

  Ohara Pharmaceutical is introduced in Newsweek International Edition